This study will investigate the pharmacokinetics and safety of RoActemra/Actemra (tocilizumab) in patients less than 2 years old with active systemic juvenile idiopathic arthritis. Patients will receive RoActemra/Actemra infusions every 2 weeks. The anticipated time on study treatment is 12 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01455701?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
